A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HH-006 in Healthy Volunteers

Exclusion Criteria

• •History of anaphylaxis or other significant allergy in the opinion of the Investigator or known allergy or hypersensitivity to any of the components of the IP
• •History of drug, alcohol, or substance abuse
• •Any history of liver disease or known hepatic, or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
• •Any history of anaphylaxis, severe allergic reaction, neutralizing antibody generations, or hypersensitivity to albumin or any protein-based therapeutics such as natalizumab (Tysabri) or any other monoclonal antibodies
• •Any previous exposure to chimeric, humanized, or human monoclonal antibody, whether licensed or not
• •Medical history of active infection (acute or chronic)
• •Any safety concern or personal condition that is inappropriate for the study participation per the Investigator's judgement.